In clinical practice for individuals with T1D, the adjunctive use of SGLT2 inhibitors is mainly aimed at improving glycemic control by decreasing glucose variability, body weight, and insulin dosage. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.